Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 22821 | 312 | 25.2 | 63% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 708 | 12194 | CALCIUM ANTAGONISTS//AMLODIPINE//ISRADIPINE |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | ISRADIPINE | Author keyword | 20 | 23% | 24% | 76 |
| 2 | CAS 75695 93 1 | Author keyword | 9 | 83% | 2% | 5 |
| 3 | DENSITY DEPENDENT GROWTH INHIBITION | Author keyword | 3 | 60% | 1% | 3 |
| 4 | GATED RADIONUCLIDE ANGIOGRAPHY | Author keyword | 2 | 67% | 1% | 2 |
| 5 | LOMIR SROR | Author keyword | 1 | 100% | 1% | 2 |
| 6 | NRK FIBROBLASTS | Author keyword | 1 | 50% | 1% | 2 |
| 7 | PHENOTYPIC TRANSFORMATION | Author keyword | 1 | 23% | 1% | 3 |
| 8 | BLACK HYPERTENSIVES | Author keyword | 1 | 50% | 0% | 1 |
| 9 | EVENT BASED TRIALS | Author keyword | 1 | 50% | 0% | 1 |
| 10 | ISRADIPINE CLINICAL STUDIES | Author keyword | 1 | 50% | 0% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | ISRADIPINE | 20 | 23% | 24% | 76 | Search ISRADIPINE | Search ISRADIPINE |
| 2 | CAS 75695 93 1 | 9 | 83% | 2% | 5 | Search CAS+75695+93+1 | Search CAS+75695+93+1 |
| 3 | DENSITY DEPENDENT GROWTH INHIBITION | 3 | 60% | 1% | 3 | Search DENSITY+DEPENDENT+GROWTH+INHIBITION | Search DENSITY+DEPENDENT+GROWTH+INHIBITION |
| 4 | GATED RADIONUCLIDE ANGIOGRAPHY | 2 | 67% | 1% | 2 | Search GATED+RADIONUCLIDE+ANGIOGRAPHY | Search GATED+RADIONUCLIDE+ANGIOGRAPHY |
| 5 | LOMIR SROR | 1 | 100% | 1% | 2 | Search LOMIR+SROR | Search LOMIR+SROR |
| 6 | NRK FIBROBLASTS | 1 | 50% | 1% | 2 | Search NRK+FIBROBLASTS | Search NRK+FIBROBLASTS |
| 7 | PHENOTYPIC TRANSFORMATION | 1 | 23% | 1% | 3 | Search PHENOTYPIC+TRANSFORMATION | Search PHENOTYPIC+TRANSFORMATION |
| 8 | BLACK HYPERTENSIVES | 1 | 50% | 0% | 1 | Search BLACK+HYPERTENSIVES | Search BLACK+HYPERTENSIVES |
| 9 | EVENT BASED TRIALS | 1 | 50% | 0% | 1 | Search EVENT+BASED+TRIALS | Search EVENT+BASED+TRIALS |
| 10 | ISRADIPINE CLINICAL STUDIES | 1 | 50% | 0% | 1 | Search ISRADIPINE++CLINICAL+STUDIES | Search ISRADIPINE++CLINICAL+STUDIES |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | PN 200 110 ISRADIPINE | 18 | 83% | 3% | 10 |
| 2 | PN 200 110 | 12 | 54% | 5% | 15 |
| 3 | CALCIUM ANTAGONIST ISRADIPINE | 11 | 78% | 2% | 7 |
| 4 | INTRAVENOUS ISRADIPINE | 4 | 67% | 1% | 4 |
| 5 | PHENOTYPIC TRANSFORMATION | 3 | 40% | 2% | 6 |
| 6 | CALCIUM ANTAGONIST PN 200 110 | 2 | 67% | 1% | 2 |
| 7 | SPIRAPRIL | 2 | 67% | 1% | 2 |
| 8 | RELEASE ISRADIPINE | 1 | 100% | 1% | 2 |
| 9 | DIHYDROPYRIDINE CALCIUM ANTAGONIST | 1 | 17% | 2% | 7 |
| 10 | NRK FIBROBLASTS | 1 | 25% | 1% | 4 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| ISRADIPINE - AN UPDATE OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN THE TREATMENT OF MILD-TO-MODERATE HYPERTENSION | 1995 | 26 | 139 | 48% |
| ISRADIPINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN CARDIOVASCULAR-DISEASE | 1990 | 89 | 145 | 37% |
| Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals | 2005 | 4 | 12 | 42% |
| ISRADIPINE | 1991 | 2 | 59 | 59% |
| ISRADIPINE - A REVIEW OF ITS ANTIHYPERTENSIVE AND OTHER PROPERTIES | 1992 | 3 | 117 | 39% |
| PY 108-068 - A CALCIUM-ANTAGONIST WITH AN UNUSUAL PATTERN OF CARDIOVASCULAR ACTIVITY | 1985 | 15 | 16 | 50% |
| Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine | 2011 | 24 | 103 | 3% |
| CALCIUM-ANTAGONISTS, VASOCONSTRICTORS AND THE PERIPHERAL-CIRCULATION | 1987 | 3 | 65 | 26% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | S TEXAS ADDICT TECHNOL | 1 | 50% | 0.3% | 1 |
| 2 | PL MATH HUMAN | 0 | 33% | 0.3% | 1 |
| 3 | SUPERACID GRP | 0 | 33% | 0.3% | 1 |
| 4 | CNRS UMR 7285 IC2MP | 0 | 25% | 0.3% | 1 |
| 5 | CNRS ERL 7368 | 0 | 17% | 0.3% | 1 |
| 6 | ELE OMAGNETISM MAT PHYS | 0 | 13% | 0.3% | 1 |
| 7 | ORGAN SYNTH TEAM | 0 | 10% | 0.3% | 1 |
| 8 | PRACT ARTS EDUC | 0 | 10% | 0.3% | 1 |
| 9 | HYPERTENS CLIN PHARMACOL SECT | 0 | 100% | 0.3% | 1 |
| 10 | MED PHARMACOL GIVEN BLDG | 0 | 100% | 0.3% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000256201 | FELODIPINE//NORMOTENSIVE VOLUNTEERS//ARANIDIPINE |
| 2 | 0.0000186964 | ELGODIPINE//NISOLDIPINE//GALLOPAMIL |
| 3 | 0.0000161583 | DIHYDROPYRIDINE TYPE CALCIUM CHANNEL BLOCKER//ETAFTORON//HOSP XIAMEN AFFILIATED 1 |
| 4 | 0.0000151618 | MEBUDIPINE//BARNIDIPINE HYDROCHLORIDE//BARNIDIPINE |
| 5 | 0.0000150351 | ANTIOXIDANT PHARMACOL//NITROSONIFEDIPINE//MYOCYTE MIGRATION |
| 6 | 0.0000107810 | BDF 9148//DPI 201 106//NA CHANNEL MODULATORS |
| 7 | 0.0000100481 | AMLODIPINE//DILTIAZEM CR//BESYLATE |
| 8 | 0.0000093815 | CLEVIDIPINE//HYPERTENSIVE EMERGENCY//HYPERTENSIVE CRISIS |
| 9 | 0.0000090670 | LERCANIDIPINE//LACIDIPINE//LERCANIDIPINE HYDROCHLORIDE |
| 10 | 0.0000067984 | SR 33557//SR33805//H 3PN200 110 |